We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for nivolumab (Bristol-Myers Squibb Australia Pty Ltd)
Active ingredients
nivolumab
Date of review outcome
Lapse date
Type
Priority Review
Indication
For the adjuvant treatment of Stage III/IV melanoma in patients who have undergone complete resection.
Registration date